Free Trial
NASDAQ:GHRS

GH Research Q4 2025 Earnings Report

GH Research logo
$21.42 +0.41 (+1.93%)
As of 01:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GH Research EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.29
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Thursday, March 5, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

GH Research's Q1 2026 earnings is estimated for Friday, May 8, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

GH Research Earnings Headlines

Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses an emerging potential $10 trillion technology backed by Elon Musk and Sam Altman. This breakthrough could completely replace our need for foreign oil - and send one small group of stocks soaring in the process.tc pixel
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS) Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression. An additional preclinical candidate, GH002, is being developed for broader indications including anxiety, cognitive impairment and substance use disorders. GH Research employs a proprietary platform to optimize dosing, formulation delivery and real-time patient monitoring.

Founded in 2017 by biotechnology entrepreneur Christian Angermayer, GH Research operates research facilities in Ireland and maintains collaborations with academic institutions and contract research organizations across Europe and North America. The executive leadership team combines expertise in psychiatry, neuroscience and drug development to advance the company’s pipeline.

GH Research engages with regulatory authorities in multiple jurisdictions as it plans to initiate later-stage clinical trials and pursue strategic partnerships. The company’s goal is to bring innovative, psychedelic-derived therapeutics to patients worldwide who face debilitating psychiatric conditions.

View GH Research Profile